/ANNX
ANNX Stock - Annexon, Inc.
Healthcare|BiotechnologyNASDAQ
$5.17+7.26%
+$0.35 (+7.26%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+132.1%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.12 – $5.22
TARGET (TP)$12.00
STOP LOSS$4.76
RISK/REWARD1:16.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.21
52W High$5.66
52W Low$1.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,454,000 | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-154,073,000 | $-143,723,000 | $-145,599,000 | $-130,713,000 | $-63,469,000 |
| Net Income | $-138,200,000 | $-134,237,000 | $-141,947,000 | $-130,323,000 | $-63,412,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.01 | $-1.77 | $-2.60 | $-3.34 | $-3.70 |
Company Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$10
Average Target
↑ 85.1% Upside
Now
$3
Low
$10
Average
$15
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 1st 2024 | JP Morgan | Upgrade | Overweight | $11 |
| December 21st 2023 | BofA Securities | Upgrade | Buy | $6← $4 |
| October 30th 2023 | Wells Fargo | Initiation | Overweight | $11 |
| May 26th 2023 | BofA Securities | Downgrade | Neutral | $3← $8 |
| May 25th 2023 | JP Morgan | Downgrade | Neutral | $9← $19 |
| September 16th 2022 | Jefferies | Initiation | Buy | $12 |
| September 9th 2022 | BTIG Research | Initiation | Buy | $15 |
Earnings History & Surprises
ANNXBeat Rate
50%
Last 18 quarters
Avg Surprise
+3.4%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.36vs$-0.45
Q2 24
+34.4%
$-0.21vs$-0.32
Q3 24
0.0%
$-0.23vs$-0.23
Q4 24
+3.8%
$-0.25vs$-0.26
Q1 25
-17.9%
$-0.33vs$-0.28
Q2 25
-23.3%
$-0.37vs$-0.30
Q3 25
+5.6%
$-0.34vs$-0.36
Q4 25
-8.8%
$-0.37vs$-0.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.32 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.34 | $-0.37 | -8.8% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.36 | $-0.34 | +5.6% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.30 | $-0.37 | -23.3% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.28 | $-0.33 | -17.9% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.23 | $-0.23 | 0.0% | = MET |
Q2 2024 | May 13, 2024 | $-0.32 | $-0.21 | +34.4% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-0.45 | $-0.36 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.50 | $-0.43 | +14.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.52 | $-0.52 | 0.0% | = MET |
Q1 2023 | Mar 6, 2023 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.87 | $-0.51 | +41.4% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.94 | $-0.96 | -2.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-1.00 | $-0.92 | +8.0% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.90 | $-0.97 | -7.8% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.88 | $-0.93 | -5.7% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.68 | $-0.82 | -20.6% | ✗ MISS |
Latest News
Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17
📈 PositiveBenzinga•Dec 2, 2025, 02:06 PM
Annexon stock rises after director purchases shares
📈 PositiveSeeking Alpha•Nov 20, 2025, 05:02 PM
Annexon shares are trading higher after Wells Fargo maintained the stock with an Overweight rating and raised its price target from $14 to $27.
📈 PositiveBenzinga•Nov 19, 2025, 07:42 PM•Also:
Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $27
📈 PositiveBenzinga•Nov 19, 2025, 07:12 PM•Also:
Annexon shares are trading lower after the company announced the pricing of its $75 million public offering of 25,096,153 shares at $2.60 per share and 3.75 million prefunded warrants at $2.599
📉 NegativeBenzinga•Nov 13, 2025, 02:24 PM
Reported Earlier, Annexon Prices $75M Public Offering Of 25,096,153 Shares At $2.60 And 3.75M Pre Funded Warrants At $2.599
➖ NeutralBenzinga•Nov 13, 2025, 07:02 AM
Annexon Announces Proposed Public Offering Of $75M Shares Of Common Stock Or Pre-Funded Warrants
➖ NeutralBenzinga•Nov 12, 2025, 09:32 PM
Annexon Q3 EPS $(0.37) Misses $(0.34) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:30 PM
Annexon Narrows Loss in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 09:23 PM
Frequently Asked Questions about ANNX
What is ANNX's current stock price?
Annexon, Inc. (ANNX) is currently trading at $5.17 per share. The stock has moved +7.26% today.
What is the analyst price target for ANNX?
The average analyst price target for ANNX is $12.00, based on 1 analyst.
What sector is Annexon, Inc. in?
Annexon, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ANNX's market cap?
Annexon, Inc. has a market capitalization of $0.62 billion, making it a small-cap company.
Does ANNX pay dividends?
No, Annexon, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
Explore stocks similar to ANNX for comparison